Clearance Summary
OptiScanner® 5000 Glucose Monitoring System received FDA 510(k) clearance under submission number K192785, sponsored by Optiscan Biomedical Corporation. The device was reviewed via the Traditional premarket notification pathway and assigned to the General Hospital review panel. The statutory decision date of record is 2020-02-05.
- Submission: K192785
- Applicant / Sponsor: Optiscan Biomedical Corporation
- Clearance pathway: Traditional
- Review panel: General Hospital
- Device class: Class II
- Regulation citation: 21 CFR 880.5725
- Decision date: 2020-02-05
Classification & Regulation
This clearance is catalogued under FDA product code LZF and 21 CFR 880.5725, within the General Hospital review panel as a Class II device.